deltatrials
Terminated PHASE3 NCT00064649

Minimally Invasive Surgical Therapy for BPH

Minimally Invasive Surgical Therapy Consortium for Benign Prostatic Hyperplasia

Sponsor: Diagnostic Ultrasound

Conditions Benign Prostatic Hyperplasia
Interventions Finasteride and Alfuzosin Transurethral Microwave Thermotherapy (TUMT) Transurethral Needle Ablation (TUNA) Therapy
Updated 7 times since 2017 Last updated: Jan 12, 2010 Started: Apr 30, 2004 Completion: Jun 30, 2006

Listed as NCT00064649, this PHASE3 trial focuses on Benign Prostatic Hyperplasia and remains terminated or withdrawn. Sponsored by Diagnostic Ultrasound, it has been updated 7 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Jun 2022 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Jan 2021 — Jun 2022 [monthly]

    Terminated PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE3

    First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Diagnostic Ultrasound
  • Medtronic
  • Merck Sharp & Dohme LLC
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Sanofi-Synthelabo
  • Urologix
Data source: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Chicago, United States
  • • Dallas, United States
  • • Denver, United States
  • • Houston, United States
  • • Milwaukee, United States
  • • New York, United States
  • • Rochester, United States